Jaguar Health Inc (Nasdaq:JAGX) has announced that its pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy has achieved an impressive 90% patient enrollment. This marks a major milestone in the development of this innovative treatment.
Jaguar’s President and CEO, Lisa Conte, is pleased to report that enrollment in the OnTarget trial has skyrocketed to over 90%, a remarkable feat achieved in just one week since announcing 80% enrollment on March 27th.
The company’s efforts to expand the trial to new international locations including Eastern Europe, Argentina, and Taiwan have proven highly successful, and they now anticipate 256 patients will complete the trial by mid-second quarter of 2023.
The OnTarget trial, a placebo-controlled study, is investigating if crofelemer’s novel mechanism of action – the modulation of two chloride ion channels in the gastrointestinal tract – can reduce or even eliminate chronic diarrhea caused by cancer therapies.
The Company hopes that the results of this trial will confirm that cancer-related diarrhea is an ongoing issue, making it difficult for patients to stay on their treatment regimens for optimal outcomes.
About Cancer Therapy-Related Diarrhea
Diarrhea is a common and potentially dangerous side effect of targeted cancer therapy, such as epidermal growth factor receptor (EGFR) antibodies, tyrosine kinase inhibitors (TKIs) and CDK 4/6 inhibitors.
It can cause dehydration, infections, and even lead to patients having to take drug holidays or reduce their therapeutic dose, which can have a detrimental effect on their outcome. Patients undergoing cancer treatment therefore need to be aware of the risk of diarrhea, and take steps to prevent and manage it.
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is an innovative pharmaceuticals company that is committed to developing novel, plant-based, sustainably-sourced prescription medicines to address GI distress and other chronic, debilitating illnesses.
Our subsidiary, Napo Pharmaceuticals, Inc., is leading the way in harnessing the power of plants harvested responsibly from rainforest areas to create safe and effective pharmaceuticals. Our groundbreaking crofelemer drug product is currently undergoing an ongoing pivotal Phase 3 clinical trial as a prophylactic for diarrhea in adult cancer patients receiving targeted therapy.
Furthermore, Jaguar Health has established Napo Therapeutics S.p.A. in Milan, Italy to further expand the availability of crofelemer in Europe. We at Jaguar Health are proud of our commitment to providing quality care to both people and animals.